Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days

Anti-Cancer Drugs

Volumn 13, Issue 8, 2002, Pages 819-825

  Muggia, Franco M ^a   Liebes, Leonard ^a   Hazarika, Maitreyee ^a   Wadlere, Scott ^a   Hamilton, Anne ^a   Hornreich, Gila ^a   Sorich, Joan ^a   Chiang, Chung ^a   Newman, Elliot ^a   Potmesil, Milan ^a   Hochster, Howard ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

9 Aminocamptothecin; Intraperitoneal; Topoisomerase I

Indexed keywords

9 AMINOCAMPTOTHECIN; DNA TOPOISOMERASE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOLOGY; DOSE RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MALE; MONONUCLEAR CELL; NEUTROPENIA; PERITONEUM CANCER; PRIORITY JOURNAL; SYNCOPE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0036746896     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200209000-00006     Document Type: Article

References (13)

1. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-5.
2. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-7.
3. Armstrong DK, Bundy BN, Baergen R, et al. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (i.p.) cisplatin and i.p. paclitaxel in optimal stage III epithelial ovarian cancer (EOC): a Gynecologic Oncology Group trial (GOG 172). Proc Am Soc Clin Oncol 2002; 21: 201a (abstr 803).
4. Gadducci A, Carnino F, Chiara S, et al. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest. Gynecol Oncol 2000; 76: 157-62.
5. Muggia F, Liebes L, Potmesil M, et al. Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin. Ann NY Acad Sci 2000; 922: 178-87.
6. Plaxe SC, Christen RD, O'Quigley J, et al. Phase I and pharmacokinetic study of intraperitoneal topotecan. Invest New Drugs 1998; 16: 147-53.
7. Eder JP, Rubin E, Stone R, et al. Trials of 9-amino-20(S)-camptothecin in Boston. Ann NY Acad Sci 1996; 803: 247-55.
8. Hochster H, Potmesil, M, Leibes L. A Phase I study of 9-amino-camptothecin (9-AC) by prolonged infusion of 21 days. In: Proc 9th NCI-EORTC Symp on New Drugs in Cancer Therapy 1996: 130.
9. Hochster H, Liebes L, Speyer J, et al. Phase I and pharmacodynamic study of prolonged infusion 9-amino-camptothecin (9-AC) in two formulations [Meeting abstract]. J Clin Oncol 1997; 16: 16.
10. Muggia FM, LePoidevin E, Jeffers S, et al. Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography. Ann Oncol 1992; 3: 149-54.
11. Supko JG, Malspeis L. Liquid chromatography analysis of 9-aminocamptothecin in plasma monitored by fluorescence induced upon postcolumn acidification. J Liq Chromatogr Clin Anal 1992; 15: 3261-72.
12. Liebes L, Potmesil M, Kim T, et al. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan. Clin Cancer Res 1998; 4: 545-57.
13. Takimoto CH, Klecker RW, Dahut WL, et al. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J Chromatogr B: Biomed Appl 1994; 655: 97-104.